The Latest News from Cleveland HeartLab
Quest Diagnostics to accelerate cardiovascular disease biomarker discovery as part of One Brave Idea™ initiative to end coronary heart diseaseNovember 13, 2018
Cleveland HeartLab and Quest Diagnostics Forming Base for Quest’s National Cardiometabolic Center of ExcellenceOctober 18, 2017
Cleveland HeartLab Launches Only Clinical Test for Measuring TMAO, an Important Measure of Gut Dysfunction that is Associated with Cardiovascular Disease RiskFebruary 16, 2016
Cleveland HeartLab Partnering with Procter & Gamble and Cleveland Clinic to Advance Discovery in Heart Disease with TMAO TestingAugust 19, 2015
Read More News from Cleveland HeartLab
CLEVELAND HEARTLAB'S THREE KEY AREAS OF FOCUS:
InnovationWe maintain a robust research and development program that partners with leading academic and medical institutions to bring unique biomarker technologies to market.
- ADMA/SDMA Testing
- TMAO Testing
- Coming Soon! HDL Proteome
InflammationLipids only predict about 50% of those that go on to have heart attacks or strokes. Measuring inflammation levels can help identify ‘hidden’ risk that may be missed with standard lipid testing.
EducationWe are committed to educating customers and the community on the advancements in identifying cardiovascular risk.
The Response to Injury Hypothesis
— Dr. Russell Ross (1976)
Dr. Ross's "Response to Injury Hypothesis" provided insight into the initiation and subsequent progression of cardiovascular disease. Briefly, cardiovascular disease is initiated through increased cholesterol and its subsequent oxidation leading to injury of the artery wall. The body responds to the injury with an inflammatory response designed to remove cholesterol from the artery wall. This process becomes dysregulated and ultimately potentiates the progression of cholesterol deposition and vulnerable plaque formation, placing an individual at increased risk of plaque rupture and subsequent heart attack or stroke.